{"DataElement":{"publicId":"2524777","version":"1","preferredName":"Acute Myelogenous Leukemia Response Criteria","preferredDefinition":"Text description of acute myelogenous leukemia status as a result of the effects from treatment or intervention.","longName":"AML_RESP_CRIT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2190138","version":"1","preferredName":"Leukemia Disease Response","preferredDefinition":"information related to leukemia disease response.","longName":"LEUK_DZ_RESP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206719","version":"1","preferredName":"Leukemia Diseases and Disorders","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C3161:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-01B3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6E12CB1-3713-3865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2524774","version":"1","preferredName":"Acute Myelogenous Leukemia Response Criteria","preferredDefinition":"Basis for description of acute myelogenous leukemia status as a result of the effects occurring following treatment or intervention.","longName":"AML_RESP_CRIT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"72","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Morphologic Leukemia - Free State","valueDescription":"Morphologic Leukemia - Free State","ValueMeaning":{"publicId":"2581112","version":"1","preferredName":"Morphologic Leukemia - Free State","longName":"2581112","preferredDefinition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Leukemia-Free State","conceptCode":"C123597","definition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF50-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Morphologic Complete Remission","valueDescription":"Morphologic Complete Remission","ValueMeaning":{"publicId":"2581113","version":"1","preferredName":"Morphologic Complete Remission","longName":"2581113","preferredDefinition":"The disappearance of all signs of cancer, supported by morphological analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Response","conceptCode":"C123595","definition":"The disappearance of all signs of cancer, supported by morphological analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF5C-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","ValueMeaning":{"publicId":"2581114","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","longName":"2581114","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF68-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Partial Remission (PR)","valueDescription":"Partial Remission (PR)","ValueMeaning":{"publicId":"2581115","version":"1","preferredName":"Partial Remission (PR)","longName":"2581115","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF74-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Treatment Failure or Progressive Disease (PD)","valueDescription":"Treatment Failure or Progressive Disease (PD)","ValueMeaning":{"publicId":"2581116","version":"1","preferredName":"Treatment Failure or Progressive Disease (PD)","longName":"2581116","preferredDefinition":"The lack of expected or desired effect related to a therapy.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lack of Efficacy","conceptCode":"C48226","definition":"The lack of expected or desired effect related to a therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF80-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Recurrence","valueDescription":"Recurrence","ValueMeaning":{"publicId":"2565643","version":"1","preferredName":"Recurrence","longName":"2565643","preferredDefinition":"To occur again.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrence","conceptCode":"C3352","definition":"Happening again (especially at regular intervals).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CD78-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-20","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-02-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF8C-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Not Evaluable (NE)","valueDescription":"Not Evaluable (NE)","ValueMeaning":{"publicId":"2581117","version":"1","preferredName":"Not Evaluable (NE)","longName":"2581117","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FF98-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Not Assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FFA4-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"Not applicable per protocol (NP)","valueDescription":"Not applicable per protocol (NP)","ValueMeaning":{"publicId":"2581118","version":"1","preferredName":"Not applicable per protocol (NP)","longName":"2581118","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1ED98BA2-FFB0-26B5-E044-0003BA3F9857","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"REEVESD","dateModified":"2006-10-02","deletedIndicator":"No"},{"value":"CR without minimal residual disease","valueDescription":"Minimal Residual Disease Negativity Complete Remission","ValueMeaning":{"publicId":"6146105","version":"1","preferredName":"Minimal Residual Disease Negativity Complete Remission","longName":"6146105","preferredDefinition":"Absence of residual disease based on laboratory techniques.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease Negativity","conceptCode":"C124428","definition":"Absence of residual disease based on laboratory techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6807F073-DF98-53F1-E053-F662850AA2A9","latestVersionIndicator":"Yes","beginDate":"2018-03-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6807F073-DFB1-53F1-E053-F662850AA2A9","beginDate":"2018-03-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2524773","version":"1","preferredName":"Acute Myeloid Leukemia Response Criteria","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.:Criteria; a basis for comparison; a reference point against which other things can be evaluated.","longName":"C3171:C25755:C25466","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EDA75FE-96DD-2324-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"ONEDATA","dateModified":"2006-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EDA75FE-96EE-2324-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"AML Response Assessment","type":"Preferred Question Text","description":"AML Response Assessment","url":null,"context":"CCR"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Objective Status at this evaluation","url":null,"context":"ECOG-ACRIN"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"AML Response","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"1ED995FB-EE1D-27B3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"SOKKERL","dateModified":"2018-04-09","changeDescription":"Approved by CCR for Released status on 10.3.2006.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}